BioSpace News Archive

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, announced the completion of a $40 million Series B financing round.

Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed President and Chief Executive Officer.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.

Asher Biotherapeutics, Inc. (Asher Bio) , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Andrea Pirzkall, M.D., as its first Chief Medical Officer.

ATCC to collaborate with Gennova Biopharmaceuticals, the U.S. Food and Drug Administration, Ohio State University, and McGill University on a Leishmania donovani diagnostic test and Leishmania major vaccine.

Guardant Health, Inc. announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.

Alpha Cognition Inc. is pleased to announce the discovery of two GEM combinations, ALPHA-0702 and ALPHA-0802, and positive preclinical data from each candidate therapy.

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta ® (Pertuzumab) and Prolia ® /Xgeva ® (Denosumab) Biosimilar Candidates.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO).

Promore Pharma AB announces today that the last clinic visit has been carried out for the subjects who participated in the company’s phase II study PHSU05 with ensereptide against skin.